Iovance Biotherapeutics Inc Cash Flow Conversion Efficiency
Iovance Biotherapeutics Inc cash flow conversion efficiency. Based on the latest financial reports, Iovance Biotherapeutics Inc (IOVA) has a cash flow conversion efficiency ratio of -0.112x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-78.70 Million) by net assets ($702.29 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Iovance Biotherapeutics Inc (2008–2024)
Cash flow conversion efficiency of Iovance Biotherapeutics Inc from 2008 to 2024. This chart illustrates how Iovance Biotherapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View IOVA stock price for real-time trading data and today's change.
Iovance Biotherapeutics Inc Cash Flow Conversion Ratio Explained
Iovance Biotherapeutics Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Iovance Biotherapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Iovance Biotherapeutics Inc ranked by their cash flow conversion efficiency. Also see Iovance Biotherapeutics Inc (IOVA) market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
E2open Parent Holdings Inc
NYSE:ETWO
|
0.046x |
|
Ningbo Kangqiang Electronics Co Ltd
SHE:002119
|
0.001x |
|
Hbt Financial Inc
NASDAQ:HBT
|
0.032x |
|
WEIBO CORP. A
F:2WB
|
N/A |
|
Abacus Storage King
AU:ASK
|
0.012x |
|
alstria office REIT-AG
XETRA:AOX
|
-0.004x |
|
Hotel101 Global Holdings Corp. Class A Ordinary Shares
NASDAQ:HBNB
|
N/A |
|
Elang Mahkota Teknologi Tbk
JK:EMTK
|
-0.013x |
Annual Cash Flow Conversion Efficiency for Iovance Biotherapeutics Inc (2008–2024)
The table below shows the annual cash flow conversion efficiency of Iovance Biotherapeutics Inc from 2008 to 2024. Review IOVA free cash flow to operating cash ratio to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $710.40 Million | $-352.98 Million | -0.497x | +19.72% |
| 2023-12-31 | $584.61 Million | $-361.82 Million | -0.619x | -5.63% |
| 2022-12-31 | $499.64 Million | $-292.76 Million | -0.586x | -59.80% |
| 2021-12-31 | $621.66 Million | $-227.94 Million | -0.367x | -17.35% |
| 2020-12-31 | $656.50 Million | $-205.13 Million | -0.312x | +41.21% |
| 2019-12-31 | $298.97 Million | $-158.89 Million | -0.531x | -144.70% |
| 2018-12-31 | $466.19 Million | $-101.25 Million | -0.217x | +59.86% |
| 2017-12-31 | $145.48 Million | $-78.71 Million | -0.541x | -176.44% |
| 2016-12-31 | $166.92 Million | $-32.67 Million | -0.196x | -10.76% |
| 2015-12-31 | $104.02 Million | $-18.38 Million | -0.177x | +8.21% |
| 2014-12-31 | $44.85 Million | $-8.63 Million | -0.193x | +7.46% |
| 2013-12-31 | $17.60 Million | $-3.66 Million | -0.208x | -205.06% |
| 2012-12-31 | $-11.32 Million | $-2.24 Million | 0.198x | -59.11% |
| 2011-12-31 | $-12.78 Million | $-6.19 Million | 0.484x | +149.77% |
| 2010-12-31 | $638.09K | $-620.80K | -0.973x | -190.83% |
| 2009-12-31 | $-13.49K | $-14.45K | 1.071x | +104.27% |
| 2008-12-31 | $2.28K | $-57.30K | -25.089x | -- |
About Iovance Biotherapeutics Inc
Iovance Biotherapeutics, Inc., a commercial-stage biopharmaceutical company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic me… Read more